Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05538754 · ClinicalTrials.gov registry record · NA
Post-Market Evaluation of the EVO ICL
A NA study of Myopia and Myopic Astigmatism, sponsored by Staar Surgical Company.
- Completed
- Registry status
- NA
- Development phase
- 205
- Enrollment target
- 8
- Study locations
NCT05538754: Completed NA study of Myopia and Myopic Astigmatism, sponsored by Staar Surgical Company.
NCT05538754 is a NA study of Myopia and Myopic Astigmatism that has completed, run by Staar Surgical Company. The registered enrollment target is 205 participants, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (23% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05538754, a NA study of Myopia and Myopic Astigmatism, has completed, sponsored by Staar Surgical Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 205 participants
- Enrollment target
- 8
- Study locations
Study Summary
The objective of this study is to assess the rate of early intraocular pressure (IOP) increases following implantation of EVO/EVO+ Implantable Collamer Lens (ICL).
Primary Outcome
The number of primary (first implanted) eyes that have elevated intraocular pressure measuring ≥ 30 mmHg as assessed with applanation tonometry which is a noninvasive test that measures the pressure inside the eye by flattening a part of the cornea.
Conditions Studied
Interventions
- DEVICE EVO ICL
Study Locations (8)
Texas
- Key-Whitman Eye Center - Dallas
- Parkhurst NuVision - San Antonio
Hawaii
- Aloha Laser Vision, LLC - Honolulu
Kansas
- Durrie Vision - Overland Park
Nebraska
- Kugler Vision, PC - Omaha
Ohio
- Cleveland Eye Clinic - Brecksville
South Dakota
- Vance Thompson Vision - Sioux Falls
Utah
- The Eye Institute of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2023-10-04 |
| Phase | NA |
What the finished NCT05538754 record still lists
NCT05538754 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (23% lower).
The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 1 intervention - of which EVO ICL is the first listed.
NCT05538754 lists 8 locations in 7 states (Texas, Hawaii, Kansas).
Frequently Asked Questions
What is clinical trial NCT05538754 about?
NCT05538754 is a clinical study titled "Post-Market Evaluation of the EVO ICL". The objective of this study is to assess the rate of early intraocular pressure (IOP) increases following implantation of EVO/EVO+ Implantable Collamer Lens (ICL).
What is the current status of trial NCT05538754?
This trial is currently completed. It is a NA study. The enrollment target is 205 participants. The study started on 2022-09-23. Estimated completion is 2023-10-04.
What conditions does trial NCT05538754 study?
This clinical trial studies the following conditions: Myopia, Myopic Astigmatism.
What interventions are being tested in trial NCT05538754?
The interventions under investigation include: EVO ICL (DEVICE).
Who is sponsoring clinical trial NCT05538754?
This trial is sponsored by Staar Surgical Company, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05538754 being conducted?
This trial has 8 study locations across Hawaii, Kansas, Nebraska, Ohio, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05538754's enrollment target sits among peer trials
205 23rd of 90 higher than 68 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI